Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02299999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02299999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 7, 2014
Completion date
December 31, 2025
Enrollment
1,460 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer